Baseline Characteristics
| Characteristic | All patients (n) | PERCIST analysis (n) |
| No. of patients | 31 | 22 |
| No. of PRRT cycles | 99 | 76 |
| Median age (y) | 67 (IQR, 58.5–72.5) | 67.5 (IQR, 59.5–73.75) |
| Female | 14 (45%) | 11 (50%) |
| Type of tumor | ||
| NEN | 23 (74%) | 17 (77%) |
| Type of NEN | ||
| Small bowel | 10 (43%) | 8 (47%) |
| Pancreas | 5 (22%) | 3 (18%) |
| Colon | 2 (9%) | 2 (12%) |
| Gastrinoma | 2 (9%) | 1 (6%) |
| Insulinoma | 2 (9%) | 2 (12%) |
| Stomach | 1 (4%) | 1 (6%) |
| Unknown | 1 (4%) | 0 |
| Functional NEN | 8 (35%) | 5 (29%) |
| SSA treatment | 20 (87%) | 15 (88%) |
| Paraganglioma | 3 (10%) | 2 (9%) |
| Meningioma | 2 (6%) | 1 (9%) |
| Esthesioneuroblastoma | 1 (3%) | 1 (5%) |
| Pheochromocytoma | 1 (3%) | 1 (5%) |
| Pituitary adenoma | 1 (3%) | 0 |
| Number of cycles | ||
| 1 | 3 (10%) | 1 (5%) |
| 2 | 7 (23%) | 4 (18%) |
| 3 | 2 (6%) | 1 (5%) |
| 4 | 19 (61%) | 16 (72%) |
| Median cumulative dose (GBq) | 21.62 (IQR, 14.86–21.94) | 21.66 (IQR, 21.32–21.91) |
IQR = interquartile range.